Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00907296 · ClinicalTrials.gov registry record · Phase 2
Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 402
- Enrollment target
NCT00907296 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 402 participants.
The verdict
NCT00907296, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 402 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate the effect of romosozumab compared with placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in the midsection of the shinbone).
Interventions
- DRUG Placebo
- BIOLOGICAL Romosozumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2009-09-02 |
| Est. Completion | 2013-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00907296
The ClinicalTrials.gov registry entry for NCT00907296 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00907296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00907296 about?
NCT00907296 is a clinical study titled "Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing". The primary objective of this study is to investigate the effect of romosozumab compared with placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in the midsection of the shinbone).
What is the current status of trial NCT00907296?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 402 participants. The study started on 2009-09-02. Estimated completion is 2013-05-10.
What interventions are being tested in trial NCT00907296?
The interventions under investigation include: Placebo (DRUG), Romosozumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00907296?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.